Ultimovacs ASA: Mandatory notification of trade by primary insiders

Oslo, 11 February, 2021: Primary insiders in Ultimovacs ASA (the ‘Company’), Canica AS and Sundt AS, have today each bought 27,500 shares in the company at a price of NOK 75.60 per share.

Following this transaction, Canica AS holds 2,535,163 shares in the Company and Sundt AS holds 719,650 in the Company. Sundt AS together with its two shareholders CGS Holding AS and Helene Sundt AS hold a total of 2,483,914 shares in the Company following the transaction.

The total of 55,000 shares were sold by Vitmed AS, a company privately held by Øyvind Kongstun Arnesen, former CEO of the Company, to finance medical expenses for close family members of Øyvind Kongstun Arnesen living outside of Norway. Following this transaction, Vitmed AS holds a total of 105,000 shares in the Company.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.